Richard Duke
Chief Executive Officer at MenoGenix, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Donald Bellgrau | M | - |
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO.
The University of Colorado
| 18 years |
| Debra M. Duke | F | - |
MenoGenix, Inc.
 MenoGenix, Inc. BiotechnologyHealth Technology MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO. | 14 years |
| Daniel D. Chan | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| George Hank Brown | M | 84 |
The University of Colorado
| 19 years |
| Renae Cormier | F | 52 |
The University of Colorado
| 1 years |
| John M. Stewart | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| Paul Bunn | M | 79 |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| James Woodruff Emlen | M | - |
MenoGenix, Inc.
MenoGenix, Inc. BiotechnologyHealth Technology MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO. | - |
| Lajos Gera | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| Sandy Hicks | F | - |
The University of Colorado
| - |
| Chan H. Pollock | M | - |
The University of Colorado
| - |
| Richard Lee Lewis | M | - |
The University of Colorado
| - |
| Jeff Saywitz | M | - |
The University of Colorado
| - |
| Alan Greenberg | M | - |
The University of Colorado
| - |
| Marcelo R. Bergquist | M | - |
The University of Colorado
| - |
| Benjamin C. Schnell | M | - |
The University of Colorado
| - |
| Heidi A. Ganahl | F | - |
The University of Colorado
| - |
| Sharon Bakke | F | - |
The University of Colorado
| - |
| Raul Guisado | M | - |
The University of Colorado
| - |
| George A. Sissel | M | 87 |
The University of Colorado
| - |
| T. Richard Fort | M | - |
MenoGenix, Inc.
MenoGenix, Inc. BiotechnologyHealth Technology MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO. | - |
| Patricia Nelson Limerick | F | - |
The University of Colorado
| - |
| Robin Shandas | M | - |
The University of Colorado
| - |
| John F. Carpenter | M | - |
The University of Colorado
| - |
| Kristi S. Anseth | M | - |
The University of Colorado
| - |
| Chris Bowman | M | - |
The University of Colorado
| - |
| Leslie Leinwand | M | - |
The University of Colorado
| - |
| Mark A. Wickert | M | - |
The University of Colorado
| - |
| Peter Mariner | M | - |
The University of Colorado
| - |
| Stephen R. Daniels | M | - |
The University of Colorado
| - |
| Jaime Modiano | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
| Mary S. Randall | F | - |
The University of Colorado
| - |
| John W. Birks | M | - |
The University of Colorado
| - |
| Alexander Bracken | M | - |
The University of Colorado
| - |
| Betty R. Jackson | M | - |
The University of Colorado
| - |
| James Ehrlich | M | - |
The University of Colorado
| - |
| James A. Lemons | M | - |
The University of Colorado
| - |
| Garret Moddel | M | - |
The University of Colorado
| - |
| Dale N. Hatfield | M | 86 |
The University of Colorado
| 23 years |
| James Rothe | M | 80 |
The University of Colorado
| 38 years |
| George P. Sape | M | 79 |
The University of Colorado
| - |
| David L. Braddock | M | 79 |
The University of Colorado
| 23 years |
| Joe M. McCord | M | 79 |
The University of Colorado
| - |
| Richard Abrams | M | - |
The University of Colorado
| - |
| Errol L. Biggs | M | 83 |
The University of Colorado
| - |
| John R. Woodhull | M | 90 |
The University of Colorado
| - |
| Marvin H. Caruthers | M | 84 |
The University of Colorado
| 45 years |
| William H. Weintraub | M | 81 |
The University of Colorado
| - |
| Thomas Robert Cech | M | 76 |
The University of Colorado
| 34 years |
| Craig W. Donaldson | M | - |
The University of Colorado
| - |
| Robert B. Uhler | M | - |
The University of Colorado
| - |
| John P. Raeder | M | - |
The University of Colorado
| - |
| Wayne F. Cascio | M | - |
The University of Colorado
| - |
| Richard D. Krugman | M | - |
The University of Colorado
| - |
| Betty Arkell | F | - |
The University of Colorado
| - |
| Larry Gold | M | 82 |
The University of Colorado
| 54 years |
| David Secunda | M | - |
The University of Colorado
| - |
| Ryan A. Martens | M | 58 |
The University of Colorado
| - |
| Paul Terrence O'Rourke | M | - |
The University of Colorado
| - |
| Melissa Gonzales | F | - |
The University of Colorado
| - |
| William Barker | M | 75 |
The University of Colorado
| 16 years |
| Christopher Ozeroff | M | 65 |
The University of Colorado
| - |
| Christopher Staszak | M | - |
The University of Colorado
| - |
| David Grooms | M | - |
The University of Colorado
| - |
| Tom Gadek | M | - |
The University of Colorado
| - |
| Robert H. Keeley | M | 83 |
The University of Colorado
| 32 years |
| Lynda Gibbons | F | - |
The University of Colorado
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hubert Lacroix | M | 68 |
McGill University
| 12 years |
| Samuel Minzberg | M | 67 |
McGill University
| 11 years |
| Wolfgang Blättchen | M | 71 |
McGill University
| 9 years |
| Lito Ioannidou | F | 70 |
McGill University
| 7 years |
| I. Supomo | M | 75 |
The University of Colorado
| 5 years |
| Subarjo Joyosumarto | M | 81 |
The University of Colorado
| 4 years |
| Teck Cheong Ho | M | 65 |
McGill University
| 6 years |
| Ali Vojdani | M | - |
McGill University
| 4 years |
| Paul Arnison | M | - |
McGill University
| 6 years |
| Bill Stanimir | M | - |
McGill University
| 8 years |
| Tjay Soen Yap | M | 71 |
McGill University
| 7 years |
| Hosen S. Marjaee | M | - |
McGill University
| 5 years |
| Robert Minto | M | 82 |
McGill University
| 4 years |
| Nathan M. Stubina | M | 65 |
McGill University
| 6 years |
| Luigi Fraquelli | M | - |
McGill University
| 6 years |
| Juli Morrow | F | 70 |
McGill University
| 4 years |
| Terence S. Orstlan | M | - |
McGill University
| 6 years |
| Jean-Pierre Landry | M | - |
McGill University
| 4 years |
| Virapan Pulges | M | 64 |
The University of Colorado
| 6 years |
| Patrick C. Lincoln | M | - |
McGill University
| 8 years |
| Michel Léonard | M | 66 |
McGill University
| 7 years |
| Peter Krogh Jensen | M | 72 |
McGill University
| 7 years |
| Christopher Theodoropoulos | M | 69 |
McGill University
| 4 years |
| Terence S. Ortslan | M | 74 |
McGill University
| 6 years |
| Alberta G. Cefis | F | - |
McGill University
| 7 years |
| Gary Littlejohn | M | 68 |
McGill University
| - |
| Neil Wiener | M | - |
McGill University
| 7 years |
| Carl M. Ravinsky | M | - |
McGill University
| 5 years |
| Basile E. Papaevangelou | M | - |
McGill University
| 7 years |
| André Chabot | M | - |
McGill University
| 5 years |
| David McAusland | M | 69 |
McGill University
| 5 years |
| Ken Schapiro | M | - |
The University of Colorado
| 5 years |
| Ramie Tritt | M | - |
McGill University
| 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 71 | 71.00% |
| Canada | 29 | 29.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Duke
- Personal Network
